Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group

S. Swisher(The University of Texas MD Anderson Cancer Center), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Genvieve R. Lyons(The University of Texas MD Anderson Cancer Center), Ayşegül A. Şahin(The University of Texas MD Anderson Cancer Center), Miluska Castillo(Instituto Nacional de Enfermedades Neoplásicas), Carlos A. Castañeda(Instituto Nacional de Enfermedades Neoplásicas), Fei Yang(Roche (Switzerland)), Xiuhong Wang(Beijing University of Technology), Yun Wu(The University of Texas MD Anderson Cancer Center), Coya Tapia(The University of Texas MD Anderson Cancer Center), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Roland L. Bassett(The University of Texas MD Anderson Cancer Center)
Annals of Surgical Oncology
March 10, 2016
10.1245/s10434-016-5173-8
Cited by 132

Related Papers

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
|Nature|2015|2.9k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
|The Lancet|2020|1.1k
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|988